NASDAQ · IOVA
Iovance Biotherapeutics, Inc.
$8.36-$1.21 (-12.6%)
Iovance Biotherapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 45.64% below the high.
Loading market information…
NASDAQ · CADL · USD
Stock price, earnings
Quote as of Oct 30, 2026, 02:17 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Candel Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 40.29% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Candel Therapeutics, Inc.’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of -$0.35. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Candel Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:17 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2024 |
|---|
| Mar 13, 2025 |
| -$0.40-73.91% vs estimate |
| $0.00 |
| Q3 2024 | Nov 14, 2024 | -$0.33 | $0.00 |
|---|
THE ANALYST VIEW
10 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 3 contributors · Median target $23.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$8.36-$1.21 (-12.6%)
Iovance Biotherapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 45.64% below the high.
$13.79-$0.36 (-2.57%)
Syndax Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.13% below the high.
$8.45-$0.54 (-5.96%)
ORIC Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.41% below the high.
$7.70-$0.29 (-3.57%)
Immix Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 49.04% below the high.
$10.43-$0.11 (-1.04%)
Puma Biotechnology, Inc.’s quoted price sits in the upper half of its reported 52-week range, 9.3% below the high.
$1.40-$0.06 (-4.11%)
Century Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 53.95% below the high.
$2.24-$0.15 (-6.09%)
MacroGenics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 56.0% below the high.
$1.21+$0.00 (0.0%)
NovaBridge Biosciences’s quoted price sits in the lower half of its reported 52-week range, 76.69% below the high.
